12:00 AM
 | 
Jul 18, 2016
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Citius Pharmaceuticals sales and marketing update

Citius said it will discontinue FDA-approved Suprenza phentermine orally disintegrating tablets to treat obesity. The company noted the obesity and weight management market has “shifted” and the sympathomimetic amine anorectic “no longer meets...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >